Home > Oncology > ASCO 2021 > Gynaecological Cancers > Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer

Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer

Presented By
Dr Eugene Ahn, Cancer Treatment Centers of America, IL, USA
Conference
ASCO 2021
Trial
Phase 2, TAPUR
In the phase 2 TAPUR basket trial, the combination of pertuzumab and trastuzumab demonstrated anti-tumour activity in heavily pre-treated patients with uterine cancer with HER2 amplification and/or specific mutations. Additional study is warranted to confirm the efficacy of pertuzumab and trastuzumab in this patient population. Unlike in breast cancer, the clinical significance of HER2 gene amplification in uterine cancer is controversial since the single-agent trastuzumab has shown little activity in HER2-positive endometrial cancer. TAPUR is a phase 2 basket study (NCT02693535) evaluating the anti-tumour activity of commercially available targeted agents in patients with advanced solid cancers harbouring genomic alterations known to be drug targets. The primary endpoint of TAPUR is disease control, defined as objective response,...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on